Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole

M. Banasr, G. M.I. Chowdhury, R. Terwilliger, S. S. Newton, R. S. Duman, K. L. Behar, G. Sanacora

Research output: Contribution to journalArticle

263 Citations (Scopus)

Abstract

Growing evidence indicates that glia pathology and amino-acid neurotransmitter system abnormalities contribute to the pathophysiology and possibly the pathogenesis of major depressive disorder. This study investigates changes in glial function occurring in the rat prefrontal cortex (PFC) after chronic unpredictable stress (CUS), a rodent model of depression. Furthermore, we analyzed the effects of riluzole, a Food and Drug Administration-approved drug for the treatment of amyotrophic laterosclerosis, known to modulate glutamate release and facilate glutamate uptake, on CUS-induced glial dysfunction and depressive-like behaviors. We provide the first experimental evidence that chronic stress impairs cortical glial function. Animals exposed to CUS and showing behavioral deficits in sucrose preference and active avoidance exhibited significant decreases in 13 C-acetate metabolism reflecting glial cell metabolism, and glial fibrillary associated protein (GFAP) mRNA expression in the PFC. The cellular, metabolic and behavioral alterations induced by CUS were reversed and/or blocked by chronic treatment with the glutamate-modulating drug riluzole. The beneficial effects of riluzole on CUS-induced anhedonia and helplessness demonstrate the antidepressant action of riluzole in rodents. Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression. Our results are consistent with recent open-label clinical trials showing the drug's effect in mood and anxiety disorders. This study provides further validation of hypothesis that glial dysfunction and disrupted amino-acid neurotransmission contribute to the pathophysiology of depression and that modulation of glutamate metabolism, uptake and/or release represent viable targets for antidepressant drug development.

Original languageEnglish (US)
Pages (from-to)501-511
Number of pages11
JournalMolecular Psychiatry
Volume15
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Riluzole
Neuroglia
Glutamic Acid
Animal Models
Depression
Pathology
Pharmaceutical Preparations
Prefrontal Cortex
Antidepressive Agents
Rodentia
Anhedonia
Amino Acids
Messenger RNA
Major Depressive Disorder
United States Food and Drug Administration
Anxiety Disorders
Mood Disorders
Synaptic Transmission
Neurotransmitter Agents
Sucrose

Keywords

  • Antidepressant
  • Glia
  • Glutamate
  • Glutamate transporter
  • Metabolism
  • Stress

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Glial pathology in an animal model of depression : Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. / Banasr, M.; Chowdhury, G. M.I.; Terwilliger, R.; Newton, S. S.; Duman, R. S.; Behar, K. L.; Sanacora, G.

In: Molecular Psychiatry, Vol. 15, No. 5, 01.05.2010, p. 501-511.

Research output: Contribution to journalArticle

Banasr, M. ; Chowdhury, G. M.I. ; Terwilliger, R. ; Newton, S. S. ; Duman, R. S. ; Behar, K. L. ; Sanacora, G. / Glial pathology in an animal model of depression : Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. In: Molecular Psychiatry. 2010 ; Vol. 15, No. 5. pp. 501-511.
@article{022aebf3cb084e3e8b2020075e634f8f,
title = "Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole",
abstract = "Growing evidence indicates that glia pathology and amino-acid neurotransmitter system abnormalities contribute to the pathophysiology and possibly the pathogenesis of major depressive disorder. This study investigates changes in glial function occurring in the rat prefrontal cortex (PFC) after chronic unpredictable stress (CUS), a rodent model of depression. Furthermore, we analyzed the effects of riluzole, a Food and Drug Administration-approved drug for the treatment of amyotrophic laterosclerosis, known to modulate glutamate release and facilate glutamate uptake, on CUS-induced glial dysfunction and depressive-like behaviors. We provide the first experimental evidence that chronic stress impairs cortical glial function. Animals exposed to CUS and showing behavioral deficits in sucrose preference and active avoidance exhibited significant decreases in 13 C-acetate metabolism reflecting glial cell metabolism, and glial fibrillary associated protein (GFAP) mRNA expression in the PFC. The cellular, metabolic and behavioral alterations induced by CUS were reversed and/or blocked by chronic treatment with the glutamate-modulating drug riluzole. The beneficial effects of riluzole on CUS-induced anhedonia and helplessness demonstrate the antidepressant action of riluzole in rodents. Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression. Our results are consistent with recent open-label clinical trials showing the drug's effect in mood and anxiety disorders. This study provides further validation of hypothesis that glial dysfunction and disrupted amino-acid neurotransmission contribute to the pathophysiology of depression and that modulation of glutamate metabolism, uptake and/or release represent viable targets for antidepressant drug development.",
keywords = "Antidepressant, Glia, Glutamate, Glutamate transporter, Metabolism, Stress",
author = "M. Banasr and Chowdhury, {G. M.I.} and R. Terwilliger and Newton, {S. S.} and Duman, {R. S.} and Behar, {K. L.} and G. Sanacora",
year = "2010",
month = "5",
day = "1",
doi = "10.1038/mp.2008.106",
language = "English (US)",
volume = "15",
pages = "501--511",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Glial pathology in an animal model of depression

T2 - Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole

AU - Banasr, M.

AU - Chowdhury, G. M.I.

AU - Terwilliger, R.

AU - Newton, S. S.

AU - Duman, R. S.

AU - Behar, K. L.

AU - Sanacora, G.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Growing evidence indicates that glia pathology and amino-acid neurotransmitter system abnormalities contribute to the pathophysiology and possibly the pathogenesis of major depressive disorder. This study investigates changes in glial function occurring in the rat prefrontal cortex (PFC) after chronic unpredictable stress (CUS), a rodent model of depression. Furthermore, we analyzed the effects of riluzole, a Food and Drug Administration-approved drug for the treatment of amyotrophic laterosclerosis, known to modulate glutamate release and facilate glutamate uptake, on CUS-induced glial dysfunction and depressive-like behaviors. We provide the first experimental evidence that chronic stress impairs cortical glial function. Animals exposed to CUS and showing behavioral deficits in sucrose preference and active avoidance exhibited significant decreases in 13 C-acetate metabolism reflecting glial cell metabolism, and glial fibrillary associated protein (GFAP) mRNA expression in the PFC. The cellular, metabolic and behavioral alterations induced by CUS were reversed and/or blocked by chronic treatment with the glutamate-modulating drug riluzole. The beneficial effects of riluzole on CUS-induced anhedonia and helplessness demonstrate the antidepressant action of riluzole in rodents. Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression. Our results are consistent with recent open-label clinical trials showing the drug's effect in mood and anxiety disorders. This study provides further validation of hypothesis that glial dysfunction and disrupted amino-acid neurotransmission contribute to the pathophysiology of depression and that modulation of glutamate metabolism, uptake and/or release represent viable targets for antidepressant drug development.

AB - Growing evidence indicates that glia pathology and amino-acid neurotransmitter system abnormalities contribute to the pathophysiology and possibly the pathogenesis of major depressive disorder. This study investigates changes in glial function occurring in the rat prefrontal cortex (PFC) after chronic unpredictable stress (CUS), a rodent model of depression. Furthermore, we analyzed the effects of riluzole, a Food and Drug Administration-approved drug for the treatment of amyotrophic laterosclerosis, known to modulate glutamate release and facilate glutamate uptake, on CUS-induced glial dysfunction and depressive-like behaviors. We provide the first experimental evidence that chronic stress impairs cortical glial function. Animals exposed to CUS and showing behavioral deficits in sucrose preference and active avoidance exhibited significant decreases in 13 C-acetate metabolism reflecting glial cell metabolism, and glial fibrillary associated protein (GFAP) mRNA expression in the PFC. The cellular, metabolic and behavioral alterations induced by CUS were reversed and/or blocked by chronic treatment with the glutamate-modulating drug riluzole. The beneficial effects of riluzole on CUS-induced anhedonia and helplessness demonstrate the antidepressant action of riluzole in rodents. Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression. Our results are consistent with recent open-label clinical trials showing the drug's effect in mood and anxiety disorders. This study provides further validation of hypothesis that glial dysfunction and disrupted amino-acid neurotransmission contribute to the pathophysiology of depression and that modulation of glutamate metabolism, uptake and/or release represent viable targets for antidepressant drug development.

KW - Antidepressant

KW - Glia

KW - Glutamate

KW - Glutamate transporter

KW - Metabolism

KW - Stress

UR - http://www.scopus.com/inward/record.url?scp=77951880669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951880669&partnerID=8YFLogxK

U2 - 10.1038/mp.2008.106

DO - 10.1038/mp.2008.106

M3 - Article

C2 - 18825147

AN - SCOPUS:77951880669

VL - 15

SP - 501

EP - 511

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 5

ER -